Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q5T2R2
UPID:
DPS1_HUMAN
Alternative names:
All-trans-decaprenyl-diphosphate synthase subunit 1; Decaprenyl pyrophosphate synthase subunit 1; Decaprenyl-diphosphate synthase subunit 1; Solanesyl-diphosphate synthase subunit 1; Trans-prenyltransferase 1
Alternative UPACC:
Q5T2R2; Q53F75; Q6P473; Q86WQ8; Q9Y2W5
Background:
All trans-polyprenyl-diphosphate synthase PDSS1, also known as Decaprenyl pyrophosphate synthase subunit 1, plays a crucial role in the biosynthesis of ubiquinone (coenzyme Q10). This enzyme catalyzes the condensation of farnesyl diphosphate (FPP) and isopentenyl diphosphate (IPP) to produce prenyl diphosphates, essential for the side chain of ubiquinone-9 and ubiquinone-10.
Therapeutic significance:
PDSS1's involvement in Coenzyme Q10 deficiency, a disorder characterized by deafness, optic atrophy, and cardiac issues, highlights its potential as a therapeutic target. Understanding PDSS1's role could lead to novel treatments for this multisystem disorder.